Revolution Medicines, Inc. (NasdaqGS: RVMD)
Health Care · Biotechnology · US
$189.76
+0.87% today · +298.5% 1Y
Revolution Medicines, Inc. (NasdaqGS: RVMD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $40.67B and employs 883 people.
Over the last twelve months the share price has gained 298.5%, trading between 46.16 and 224.31.
Tweenvest scores Revolution Medicines, Inc. across four factors: quality 38/100, value 79/100. Its strongest factor is value.
RVMD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $40.67B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -8.92
- Dividend yield
- —
- Beta (5Y)
- 1.40
- 52-week high
- $224.31
- 52-week low
- $46.16
- Avg volume (3M)
- —
- Shares outstanding
- 214.34M
- Employees
- 883
- Next earnings
- —
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
- ISIN
- US76155X1000
- Founded
- 2014
- Listed since
- Feb 13, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $74.55B | $746.54 | +0.94% |
| CSL LimitedASX: CSL | $61.44B | AU$183.84 | +1.31% |
| Natera, Inc.NasdaqGS: NTRA | $57.76B | $400.71 | +2.54% |
| argenx SEENXTBR: ARGX | $51.01B | €728.40 | +3.23% |
| BeOne Medicines AGNasdaqGS: ONC | $40.30B | $354.47 | +1.24% |
| Biogen Inc.NasdaqGS: BIIB | $33.35B | $225.71 | +3.33% |
| Alnylam Pharmaceuticals, Inc.NasdaqGS: ALNY | $31.13B | $232.68 | +3.63% |
| Celltrion, Inc.KOSE: A068270 | $30.52B | ₩179,600.00 | -1.64% |
Figures last refreshed Oct 11, 2026.